Sou Hu Cai Jing·2025-05-12 11:54Core Viewpoint - The company, Haohai Biological Technology Co., Ltd., is experiencing a decline in stock price and financial performance, with a current PE ratio significantly lower than the industry average, indicating potential undervaluation in the medical device sector [1][2]. Company Summary - Haohai Biological Technology's stock closed at 51.15 yuan, down 1.63%, with a rolling PE ratio of 28.87 times and a total market capitalization of 11.928 billion yuan [1]. - The company operates in the medical device and pharmaceutical sectors, focusing on the research, production, and sales of products such as ophthalmic viscoelastic devices, artificial lenses, and hyaluronic acid [1]. - For Q1 2025, the company reported revenue of 619 million yuan, a year-on-year decrease of 4.25%, and a net profit of 90.3121 million yuan, down 7.41%, with a gross profit margin of 69.52% [1]. Industry Summary - The average PE ratio for the medical device industry is 49.84 times, with a median of 36.59 times, positioning Haohai Biological Technology at the 65th rank within the industry [1][2]. - As of the latest report, three institutions hold shares in Haohai Biological Technology, with a total of 2.4635 million shares valued at 146 million yuan [1].